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2113need for a better understanding of SCD epidemiology and
risk factors.
The pathophysiology of SCD is complex, but it is generally
believed that an abnormal cardiac substrate underlies most
cases (2,9–11). The association of cardiomyocyte injury and
SCD risk in the general population has not been studied to
date. Such investigation could have been limited by the
inability of conventional assays to detect very low levels of
circulating troponins that would reﬂect subclinical car-
diomyocyte damage.See page 2121A recently developed highly sensitive cardiac troponin T
assay (12) has allowed detection of very low levels of cir-
culating troponin, even in ambulatory asymptomatic subjects
(12,13). This biomarker of cardiomyocyte injury has been
found to be associated with adverse cardiovascular outcomes,
including heart failure and cardiovascular mortality (14–17).
We hypothesized that cardiomyocyte injury, assessed by
measures of cardiac troponin T levels by a highly sensitive
assay (hsTnT), is associated with SCD risk beyond tradi-
tional risk factors. The study hypothesis was tested in a large
prospectively followed community-based population.
Methods
Study population. The CHS (Cardiovascular Health Study)
is a longitudinal study of adults age 65 years or older at
recruitment. The rationale, design, and methods of CHS,
including information on data collection and deﬁnition of
comorbid conditions have been previously published (18,19).
Brieﬂy, the CHS population consisted of 5,888 men and
women recruited from Medicare ﬁles from 4 communities in
the United States (Forsyth County, North Carolina; Sac-
ramento County, California; Washington County, Mary-
land; and Pittsburgh, Pennsylvania). The original cohort of
participants included 5,201 subjects who were enrolled from
1989 to 1990. A minority cohort was enrolled between 1992
and 1993, which included 687 African Americans. The
cohort for current analysis included 4,431 participants who
had baseline levels of hsTnT from sera collected at enroll-
ment. Of those, 3,089 participants had follow-up measures
(2 to 3 years after the original assay) and were included in
analyses of the association between change in hsTnT levels
and SCD risk (Fig. 1). The CHS was approved by the
institutional review boards at the University of Washington
(Seattle, Washington) and participating sites. All subjects
gave written informed consent at time of enrollment.
Initial assessment, follow-up, and cardiovascular events. At
enrollment, study participants were assessed by a standardized
questionnaire that addressed variable health and behavioral
risk factors, in addition to a physical examination (19,20). For
each cardiovascular condition, self-reports were conﬁrmed
by components of the baseline examination or, if necessary,
by a validation protocol that included either review of medicalrecords or surveys of treating
physicians (19). For instance, in
addition to patient interviews, the
baseline examinations sought to
identify major Q waves or the
combination of minor Q waves
and ST-T-wave changes on elec-
trocardiograms to conﬁrm self-
reported myocardial infarction
(MI). Self-reported heart failure
was conﬁrmed by symptoms,
physical signs, and the use of both diuretics and either
digitalis or a vasodilator. Further conﬁrmation of MI or heart
failure, was sought from treating physicians by questionnaire
or from hospitals by discharge summaries, as well as by
review of medical records (19). Coronary heart disease was
deﬁned as a history of angina, coronary revascularization, or
previous MI. After the initial assessment, enrolled subjects
were contacted every 6 months for follow-up, alternating
between telephone interviews and clinic visits through 1998
and 1999 and by telephone interviews only thereafter. All
participants had resting 12-lead electrocardiograms ob-
tained at baseline, and these were repeated annually through
the last clinic visit. Echocardiograms were obtained at
baseline for the original cohort and at the study visit in 1994
and 1995 for both cohorts. In addition, discharge diagnoses
for all hospitalizations were collected. New cardiovascular
events, reported during a clinical visit, a telephone en-
counter, or from a hospital stay were conﬁrmed by obtaining
medical records and adjudicated by a centralized events
committee (20). The details on ascertainment and adjudi-
cation of death and cardiovascular events, including inci-
dent heart failure and MI, in CHS have been previously
published (20). Incident heart failure was conﬁrmed by
documentation in the medical record of a constellation of
symptoms and physical signs with supporting clinical
ﬁndings or a record of medical therapy for heart failure.
Incident MI was conﬁrmed by electrocardiographic criteria
and measures of cardiac enzymes (20). Information on
death was obtained from reviews of medical records, death
certiﬁcates, autopsy reports, and coroners’ reports; ascer-
tainment of death was 100%. Causes of death were assessed
by additional reviews of inpatient, nursing home, or hospice
records; physician questionnaires; and interviews with next
of kin. Autopsy reports were also reviewed when available.
Cardiovascular mortality was deﬁned as mortality related
to atherosclerotic heart disease, mortality following cere-
brovascular disease, or mortality from other atherosclerotic
and cardiovascular diseases including heart failure (20).
To identify SCD cases for the present study, all cases of
fatal cardiovascular death were reviewed and adjudicated by
physicians. SCD was deﬁned as a sudden instantaneous
pulseless condition, presumed to be from a malignant
ventricular arrhythmia, in a previously stable individual
without evidence of a noncardiac cause of the arrest. We a
priori sought to exclude cases with nonarrhythmic
Figure 1 Enrollment and Analysis Flow of the Study Population
hsTnT ¼ troponin T levels by highly sensitive assay.
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hypotension or advanced congestive heart failure before
death. All SCD events in this analysis occurred out of the
hospital or in the emergency room. All deaths that occurred
under hospice or nursing home care or in subjects with life-
threatening noncardiac comorbidities were not considered
SCD. Available data from death certiﬁcates, informant
interviews, physician questionnaires, coroner’s reports, and
hospital discharge summaries were reviewed, as well as
circumstances surrounding the event, to accurately classify
whether the subject had experienced SCD. For nonwitnessed
deaths, the participant must have been seen within 24 h
of the arrest in a stable condition and without evidence
of a noncardiac cause of cardiac arrest. A blinded second
physician review of a random sample of 70 of these death
records showed an 88% inter-reviewer agreement and
kappa ¼ 0.74 for SCD (21).
Cardiac troponin T assays. Details on blood sample
acquisition as well as analytical and quality assurance
methods in CHS were previously published (22). All
measurements of TnT levels were performed in a central
blood analysis laboratory. Baseline measures were obtained
from sera collected at enrollment. Follow-up measures were
performed on blood samples collected 2 to 3 years later.
Blood samples were stored at –70C to –80C and thawed
just prior to laboratory assays (maximum of 3 freeze-thaw
cycles) in April 2010. All cardiac TnT concentrations were
measured using highly sensitive TnT reagents on an Elecsys
2010 analyzer (Roche Diagnostics, Indianapolis, Indiana).
The analytical measurement range of the assay was 3 to10,000 pg/ml with an analytical coefﬁcient of variation of
10% (12). Values of hsTnT that were below the threshold of
detection were set to 2.99 for continuous analyses. The
analytical sensitivity, speciﬁcity, interferences, and precision
of the assay were previously validated (12). The value at the
99th percentile cutoff from a healthy reference population
was 13.5 pg/ml (12). The hsTnT measurements for this
study are from reagent lots not affected by the recent tech-
nical bulletin from Roche Diagnostics regarding calibration
curves of the assay for some TnT prior reagent lots (23). All
technologists performing and recording the biomarker assay
results were blinded to participants’ outcomes including
SCD.
Statistical analyses. The risk of SCD as a function of
baseline hsTnT levels was assessed in the overall population.
Furthermore, the association of change in hsTnT level with
SCD was assessed in a group of participants with serial
measures. Plasma levels of hsTnT were analyzed both as
continuous variables for which natural log–transformed
values were used, as well as categorized into 3 groups of low,
intermediate, and high risk based on their association with
SCD. The characteristics of these groups were compared by
using the chi-square test for proportions, the analysis of
variance method for normally distributed continuous vari-
ables, and the Kruskal-Wallis test for non-normally distrib-
uted continuous variables. Statistical analyses were performed
using JMP Pro (version 9.0, SAS Institute, Cary, North
Carolina) and STATA (version 12.1, StataCorp, College
Station, Texas). We considered p values of<0.05 statistically
signiﬁcant.
Figure 2 Low-, Intermediate-, and High-Risk Categories of SCD Based on hsTnT
Analysis was performed to deﬁne low- (5.00 pg/ml), intermediate- (5.01 to 12.09 pg/ml), and high- (12.10 pg/ml) risk categories of sudden cardiac death (SCD) based on
Troponin T levels by a sensitive assay (hsTnT). Hazard ratios (95% conﬁdence intervals) of SCD with increasing deciles (D1 to D10) of detectable hsTnT levels are compared with
those for subjects with undetectable levels (2.99 pg/ml). *Refers to undetectable levels to hsTnT.
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levels and SCD risk was ﬁrst tested with hsTnT levels
analyzed as a continuous variable. The 3 groups were
subsequently identiﬁed by using Cox proportional hazards
analyses of SCD risk in participants with undetectable levels
of hsTnT (n ¼ 1,442) and deciles of the population
with detectable levels (n ¼ 2,989) (Fig. 2). The risk of
SCD with increasing deciles of detectable hsTnT levels
compared with that for participants with undetectable levels
was employed to identify the low-risk group. The cutoff was
deﬁned by the decile above which there was a statistically
signiﬁcant increase in SCD risk compared with that for
participants in lower deciles and undetectable levels group.
The high-risk group was deﬁned by evaluating SCD risk with
descending deciles of detectable hsTnT levels compared with
that of the 10th decile. The cutoff was deﬁned by the decile
below which there was a statistically signiﬁcant decrease in
SCD risk compared with that for participants in upper
deciles. Kaplan-Meier curves were used to present cumulative
SCD in the previously deﬁned groups (log-rank test used for
comparison).
Covariate-adjusted Cox models were employed to study
the association of baseline hsTnT levels and SCD risk.
The ﬁrst set of multivariable analyses adjusted for demo-
graphics and baseline factors found to have a statistically
signiﬁcant relationship with SCD in univariate analyses.
These factors included: age; race (African American vs. not);sex; smoking (current vs. former vs. never); physical activity
(log-transformed kilocalories per day); previous diagnoses of
heart failure, coronary disease, MI, stroke or transient
ischemic attack; ventricular conduction delay; Q and QS
abnormalities; prolonged QT interval; qualitative left
ventricular ejection fraction (<45% vs. 45% to 55% vs.
>55%); left ventricular mass by electrocardiogram; systolic
blood pressure; serum glucose levels; serum total and high-
density lipoprotein cholesterol levels; estimated glomerular
ﬁltration rate (by the modiﬁed diet in renal disease formula);
C-reactive protein (log-transformed); N-terminal pro–
B-type natriuretic peptide (log-transformed); and use of
aspirin, antihypertensives, antiarrhythmics and digoxin.
Further details about these covariates are included in the
Online Table. The second set of multivariable analyses
additionally adjusted for incident heart failure and MI,
in a time-dependent analysis, to account for the well-
established relationship between these conditions and
SCD. Hazard ratios (HRs) and their 95% conﬁdence
intervals (CIs) are reported from the proportional hazards
models.
The association between change in hsTnT levels and
SCD risk was evaluated in Cox models as discussed previ-
ously. The change in hsTnT levels was analyzed as
a continuous variable of change per years between
measurements from baseline and adjusted for baseline levels
in multivariable models.
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deaths may have similar myocardial or coronary substrates,
we provide parallel analyses with endpoints of all-cause
mortality and nonsudden cardiovascular death.
Results
Based on the associations of deciles of hsTnT and SCD,
hsTnT was categorized into 3 groups with cutoff points atTable 1
Baseline Demographics and Clinical Characteristics of the S
Cardiovascular Health Study) Categorized According to Bas
All Subjects 5.00
n 4,431 2,039
Age, yrs 72.8  5.6 70.9  4.2
Male 40.8 25.3
Race, African American 16.3 16.6
Current smoker 10.9 12.7
Diabetes mellitus 18.4 12.3
Body mass index, kg/m2 26.8  4.8 26.7  4.7
Physical activity, kcal/day 1,031 (368, 2,243) 1,174 (450, 2,465
Coronary heart disease 19.8 13.1
Previous MI 9.6 5.9
Previous stroke 3.9 1.8
Previous TIA 3 1.8
Hypertension 45.3 38
LVEF
>55% 90.9 95.2
45%–55% 5.3 3.6
<45% 3.8 1.3
VCD 9.3 5.4
Atrial ﬁbrillation 2.8 0.9
Long QT interval 14.3 10.6
Triglycerides, mg/dl 120 (92, 164) 119 (92, 164)
HDL-C, mg/dl 54.2  15.8 56.8  15.7
Total cholesterol, mg/dl 211.2  39 217.3  38.3
LDL-C, mg/dl 129.8  35.3 133.4  35.4
NT-proBNP, ng/dl 115.9 (58.9, 238.4) 84.0 (44.6, 154.2)
C-reactive protein, mg/l 2.6 (1.3, 4.5) 2.4 (1.2, 4.3)
Estimated GFR, SI units 78.2  23.5 83.3  21.4
Fasting glucose, mg/dl 112.8  39 107.6  32.8
Systolic BP, mm Hg 137  21.8 133.2  19.9
Diastolic BP, mm Hg 70.8  11.3 70.3  10.6
Aspirin 34.3 32.1
Antihypertensives 48 40.5
Diuretics 29.2 23.2
Beta-blockers 13.3 12.1
ACE inhibitors 7.8 5.4
Antiarrhythmics
Class IA 2 1.2
Class IB 1 0.8
Class IC 0.1 0.1
Class III 0.1 0.05
Digitalis 8.7 3.7
Values are mean  SD, %, or median (IQR).
ACE ¼ angiotensin converting enzyme; BP ¼ blood pressure; GFR ¼ glomerular ﬁltration rate; HDL-C¼ h
LDL-C ¼ low-density lipoprotein cholesterol; LVEF ¼ left ventricular ejection fraction; MI ¼ myocardial in
Units; TIA ¼ transient ischemic attack; VCD ¼ ventricular conduction delay.5.01 and 12.09 pg/ml. The demographics and clinical char-
acteristics of the overall study population (n ¼ 4,431) and by
hsTnT category are summarized in Table 1. Participants were
72.8 5.6 years of age at enrollment (range 65 to 100), 40.8%
were men, and 16.3% were African Americans. Most of
participants (91%) had preserved left ventricular function
(ejection fraction >55%). Overall, higher levels of hsTnT
were associated with prevalent cardiovascular disease and
risk factors (Table 1). There were 69 (3.4% of 2,039),tudy Population (4,431 Participants From the
eline Levels of hsTnT
hsTnT Levels, pg/ml
5.01–12.09 12.10 p Value
1,498 894
73.5  5.4 76.2  6.6 <0.0001
47.9 64.3 <0.0001
13.9 19.7 0.0009
8.8 10.5 0.001
19.5 30.2 <0.0001
27.0  4.9 26.7  4.7 0.1
) 998 (349, 2,146) 735 (245, 1,785) <0.0001
21.8 31.8 <0.0001
10.0 17.3 <0.0001
3.8 8.6 <0.0001
3.2 5.7 <0.0001
49.5 54.8 <0.0001
<0.0001
90.8 81.1
5.3 9.6
4.0 9.3
8.8 19.2 <0.0001
3.6 5.8 <0.0001
14.8 22.4 <0.0001
124 (93, 163) 118 (90, 167) 0.6
52.7  15.3 50.9  15.9 <0.0001
209.1  37.9 200.9  40.6 <0.0001
128.9  34.0 122.7  36.3 <0.0001
128 (66.2, 258.1) 259.2 (11.5, 705.6) <0.0001
2.4 (1.2, 4.3) 3.1 (1.6, 7.0) <0.0001
77.5  23.1 67.6  24.9 <0.0001
113.4  34.9 123.9  53.6 <0.0001
139.2  22.0 141.7  24.3 <0.0001
71.0  11.5 71.5  12.5 0.02
35.9 36.5 0.02
51.5 60.1 <0.0001
30.4 41.1 <0.0001
14.3 14.2 0.1
9 11.3 <0.0001
2.6 3.6 <0.0001
0.9 1.3 0.5
0.07 0.2 0.6
0 0.3 0.04
9.8 18.5 <0.0001
igh-density lipoprotein cholesterol; hsTnT ¼ cardiac troponin T measured by a highly sensitive assay;
farction; NT-proBNP ¼ N-terminal pro–B-type natriuretic peptide; SI units ¼ International System of
Figure 3 Cumulative Incidence of SCD
Cumulative incidence of SCD in participants of the Cardiovascular Health Study
(n ¼ 4,431) based on baseline hsTnT. Abbreviations as in Figures 1 and 2.
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211799 (6.6% of 1,498), and 78 (8.7% of 894) cases of SCD in
the low-, intermediate-, and high-risk categories. The
cumulative hazard of SCD by hsTnT category in the
overall population is shown in Figure 3 (log-rank test
p value <0.0001).
Over a median follow-up of 13.1 years (interquartile
range 7.8, 16.3, maximum 17.1), 246 cases of SCD
occurred in the overall population (5.6%). The unadjusted
HR of SCD risk per log hsTnT increase was 2.04 (95% CI:
1.78 to 2.34, p < 0.0001). This association persisted in
covariate-adjusted Cox analyses that accounted for baseline
demographics and risk factors (HR: 1.30, 95% CI: 1.05 to
1.62, p ¼ 0.02), as well as for incident heart failure and MI
(HR: 1.26, 95% CI: 1.01 to 1.57, p ¼ 0.04).
The unadjusted HR for SCD in subjects with hsTnT
levels in the intermediate- and high-risk groups compared
with that for subjects with hsTnT levels lower than
5.00 pg/ml were 2.37 (95% CI: 1.74 to 3.23) and 4.89 (95%
CI: 3.52 to 6.80), respectively (ptrend <0.0001). This asso-
ciation persisted in multivariable analyses (Table 2) adjusting
for baseline demographics and risk factors (HR: 2.04,Table 2
Cox Proportional Hazards Analyses of SCD Risk in Cardiovas
Baseline Levels of hsTnT
Univariate
HR 95% CI p Value HR
hsTnT levels
5.00 pg/ml 1.00 (reference) <0.0001 1.00
5.01–12.09 pg/ml 2.37 1.74–3.23 1.58
12.10 pg/ml 4.89 3.52–6.80 2.04
þ1 log hsTnT 2.04 1.78–2.34 <0.0001 1.30
*Adjusted for demographics and baseline factors in association with SCD in univariate analyses: age; rac
heart failure; coronary disease; history of myocardial infarction; stroke; transient ischemic attack; ventricu
(<45% vs. 45% to 55% vs. >55%); left ventricular mass by electrocardiogram; systolic blood pressure
estimated glomerular ﬁltration rate by the modiﬁed diet in renal disease formula; C-reactive protein; N-
digoxin. yAdjusted for the factors in the previous note as well as incident heart failure and myocardial i
CI ¼ conﬁdence interval; HR ¼ hazard ratio; other abbreviations as in Table 1.95% CI: 1.31 to 3.18 and HR: 1.58, 95% CI: 1.10 to 2.28
for baseline hsTnT levels 12.10 and 5.0 to 12.09,
respectively, compared with 5.00 pg/ml, ptrend ¼ 0.001), as
well as incident heart failure and MI (HR: 1.89, 95%
CI: 1.21 to 2.95 and HR: 1.55, 95% CI: 1.08 to 2.23 for
baseline hsTnT levels 12.10 and 5.01 to 12.09, respec-
tively, compared with 5.00 pg/ml, ptrend ¼ 0.005).
In subjects with serial levels of hsTnT (n ¼ 3,089), 151
SCD cases (4.9%) occurred over a median follow-up of 11.7
years. In Cox proportional hazards analyses adjusting for
baseline hsTnT levels, the HR of SCD for every 1 pg/ml
per year increase from baseline was 1.05 (95% CI: 1.04 to
1.07, p < 0.0001). This association persisted in multivari-
able analyses that additionally adjusted for demographics
and risk factors (HR: 1.03, 95% CI: 1.01 to 1.06, p ¼ 0.02),
as well as incident heart failure and MI (HR: 1.03, 95% CI:
1.01 to 1.06, p ¼ 0.03) (Table 3).
Finally, there was a signiﬁcant association between base-
line levels of hsTnT and the risk of all-cause mortality
(HR for þ1 log[hsTnT]: 1.15, 95% CI: 1.07 to 1.23, p ¼
0.0001] and nonsudden cardiovascular death (HR for þ1
log[hsTnT]: 1.16, 95% CI: 1.02 to 1.30, p ¼ 0.02), which
persisted in covariate-adjusted models accounting for base-
line risk factors, as well as incident MI and heart failure
(Table 4). Similarly, these associations were also observed
with analyses of serial measures and change of hsTnT levels
from baseline (Table 4).Discussion
In a large community-based population followed for up to
17 years, there was a signiﬁcant graded association between
cardiac TnT levels measured by a highly sensitive assay and
long-term risk of SCD. The Kaplan-Meier curves for
cumulative SCD, based on hsTnT levels, separated very
early after enrollment and continued to diverge throughout
the duration of the study. The association between hsTnT
levels and SCD risk persisted in covariate-adjusted analyses
accounting for an extensive number of risk factors including
low ejection fraction, incident heart failure, and MI, sug-
gesting that cardiomyocyte injury increases SCD risk beyondcular Health Study Participants (n ¼ 4,431) According to
Covariate-Adjusted* Covariate-Adjustedy
95% CI p Value HR 95% CI p Value
(reference) 0.001 1.00 (reference) 0.005
1.10–2.28 1.55 1.08–2.23
1.31–3.18 1.89 1.21–2.95
1.05–1.62 0.02 1.26 1.01–1.57 0.04
e (African American vs. not); sex; smoking (current vs. former vs. never); physical activity; history of
lar conduction delay; Q and QS abnormalities; prolonged QT interval; left ventricular ejection fraction
; serum glucose levels; serum total cholesterol levels; high-density lipoprotein cholesterol levels;
terminal pro–B-type natriuretic peptide; and use of aspirin, antihypertensives, antiarrhythmics, and
nfarction.
Table 3
Cox Proportional Hazards Analyses of SCD Risk in
Cardiovascular Health Study Participants (n ¼ 3,089)
According to Serial Change in hsTnT
HR 95% CI p Value
Covariate-adjusted* 1.05 1.04–1.07 <0.0001
Covariate-adjustedy 1.03 1.01–1.06 0.02
Covariate-adjustedz 1.03 1.01–1.06 0.03
Hazard ratios are for every 1 pg/ml per year increase from baseline. *Adjusted for baseline hsTnT
levels. yAdjusted for demographics, baseline hsTnT levels and other baseline factors in association
with SCD in univariate analyses: age; race (African American vs. not); sex; smoking (current vs.
former vs. never); physical activity; history of heart failure; coronary disease; history of myocardial
infarction; stroke; transient ischemic attack; ventricular conduction delay; Q and QS abnormalities;
prolonged QT interval; left ventricular ejection fraction (<45% vs. 45% to 55% vs. >55%); left
ventricular mass by electrocardiogram; systolic blood pressure; serum glucose levels; serum total
cholesterol levels; high-density lipoprotein cholesterol levels; estimated glomerular ﬁltration rate by
the modiﬁed diet in renal disease formula; C-reactive protein; N-terminal pro–B-type natriuretic
peptide; and use of aspirin, antihypertensives, antiarrhythmics, and digoxin. zAdjusted for the
factors in the previous note as well as incident heart failure and myocardial infarction.
Abbreviations as in Tables 1 and 2.
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2118the effect of these covariates. Finally, there was a signiﬁcant
association between changes in hsTnT levels and SCD risk
even after adjustment for covariates denoting a dynamic
change in risk, which can be assessed with serial measures.
The ﬁndings are novel and have signiﬁcant clinical impli-
cations. Cardiac troponins are the preferred biomarkers for
the diagnosis of acute MI (24). Elevated levels of these
biomarkers may also be observed in other acute clinical
circumstances, in which myocardial injury may occur, and
represent an indicator of poor outcomes (25,26). The prog-
nostic value of such elevations has been also increasingly
recognized in chronic cardiac conditions, such as stable
coronary disease and heart failure (27,28). In the general
population, detectable levels of cardiac troponins by conven-
tional assays have been associated with structural heart disease
(29) and increased risk of adverse cardiovascular events andTable 4
Cox Proportional Hazards Analyses of All-Cause Mortality an
Cardiovascular Health Study Participants (n ¼ 4,431) Acco
Univariate
HR 95% CI p Value HR
All-cause mortality
hsTnT levels
 5.00 pg/ml 1.00 (reference) <0.0001 1.0
5.01–12.09 pg/ml 1.79 1.63–1.97 1.1
12.10 pg/ml 3.72 3.35–4.13 1.5
þ1 log hsTnT 1.90 1.81–1.99 <0.0001 1.2
hsTnT change, þ1 pg/ml/yr 1.05 1.05–1.06 <0.0001 1.0
Nonsudden cardiovascular death
hsTnT levels
5.00 pg/ml 1.00 (reference) <0.0001 1.0
5.01–12.09 pg/ml 2.34 1.96–2.80 1.4
12.10 pg/ml 5.65 4.69–6.82 1.8
þ1 log hsTnT 2.22 2.06–2.39 <0.0001 1.2
hsTnT change, þ1 pg/ml/yr 1.06 1.05–1.07 <0.0001 1.0
*Adjusted for demographics and baseline factors in association with SCD in univariate analyses: age; rac
heart failure; coronary disease; history of myocardial infarction; stroke; transient ischemic attack; ventricu
(<45% vs. 45% to 55% vs. >55%); left ventricular mass by electrocardiogram; systolic blood pressure
estimated glomerular ﬁltration rate by the modiﬁed diet in renal disease formula; C-reactive protein; N-
digoxin. yAdjusted for the factors in the previous note as well as incident heart failure and myocardial i
Abbreviations as in Tables 1 and 2.cardiac mortality (30–32). However, the detection thresholds
of these assays have limited the application of such ﬁndings for
clinical risk stratiﬁcation purposes (29).
The recently available hsTnT assay has allowed detection
of much lower concentrations of circulating TnT (12) and
was found to have improved accuracy for the diagnosis of MI
compared with conventional assays (33). More recent studies
have suggested that this assay may have potential beyond MI
diagnosis and may provide important information regard-
ing cardiovascular risk in various populations (14–17). In
patients with stable coronary disease and those with chronic
heart failure, circulating hsTnT levels have been linked to
cardiovascular mortality (14,15). In the general population,
cardiac troponin levels by a highly sensitive assay were found
to be associated with structural heart disease and traditional
cardiovascular risk factors (16,17), but they provided inde-
pendent prognostic information regarding incident heart
failure and cardiovascular and all-cause mortality (16,17).
The current study extends these observations to SCD risk in
the general population of older adults. This population is of
particular interest given that it contributes most of the SCD
cases to the community (2,34,35).
The pathophysiological mechanisms underlying the asso-
ciations observed in this study deserve further investigation. It
is possible that cardiomyocyte injury in ambulatory subjects
results in myocardial scarring, providing an anatomical
substrate for electrical reentry and lethal arrhythmias. Such
injury could be related to aging, clinically recognized disease
states (16), or subclinical conditions such as unrecognized
coronary disease. In fact, coronary artery disease underlies
a signiﬁcant subset of SCD cases (2,9). It is possible that
many SCD victims develop myocardial ischemia prior to
their collapse, but in contrast to those who present to thed Nonsudden Cardiovascular Death in
rding to Baseline and Serial Measures of hsTnT
Covariate-Adjusted* Covariate-Adjustedy
95% CI p Value HR 95% CI p Value
0 (reference) <0.0001 1.00 (reference) <0.0001
9 1.08–1.32 1.14 1.03–1.26
0 1.32–1.71 1.37 1.21–1.56
0 1.12–1.28 <0.0001 1.15 1.07–1.23 0.0001
3 1.02–1.04 <0.0001 1.02 1.02–1.03 <0.0001
0 (reference) <0.0001 1.00 (reference) 0.002
0 1.16–1.69 1.26 1.04–1.52
1 1.44–2.29 1.46 1.15–1.85
7 1.13–1.42 0.0001 1.16 1.02–1.30 0.02
3 1.02–1.04 <0.0001 1.02 1.01–1.03 0.003
e (African American vs. not); sex; smoking (current vs. former vs. never); physical activity; history of
lar conduction delay; Q and QS abnormalities; prolonged QT interval; left ventricular ejection fraction
; serum glucose levels; serum total cholesterol levels; high-density lipoprotein cholesterol levels;
terminal pro–B-type natriuretic peptide; and use of aspirin, antihypertensives, antiarrhythmics, and
nfarction.
JACC Vol. 62, No. 22, 2013 Hussein et al.
December 3, 2013:2112–20 Cardiomyocyte Injury and Sudden Cardiac Death
2119emergency rooms with acute coronary syndromes, SCD
victims experience a sudden circulatory collapsedmost
commonly from a life-threatening arrhythmia. The myocar-
dial or coronary substrates of such events may be similar to
those of nonsudden cardiovascular deaths. In fact, baseline
and serial measures of hsTnT in this study were found to be
associated with all-cause mortality and nonsudden cardio-
vascular deaths as well, suggesting an overlap in the patho-
physiological mechanisms leading to sudden and nonsudden
cardiovascular deaths. HR for SCD as a function of base-
line hsTnT levels appeared to be higher than those for
all-cause mortality and nonsudden cardiovascular death. CI,
however, overlapped, which precludes deﬁnitive conclusions
regarding strength of associations with SCD compared with
all-cause and nonsudden cardiovascular mortality. Impor-
tantly, hsTnT levels were associated with SCD events that
occurred up to 17 years after the initial assay. These obser-
vations, along with our observations of an association between
change in hsTnT levels and SCD, suggest that cardiac
troponin levels in ambulatory subjects may reﬂect an ongoing
myocardial injury–remodeling process that may result in
structural cardiac abnormalities that may in turn pre-dispose
to SCD. These explanations are, however, hypothetical and
further research would be required to address the mechanisms
underlying these associations.
Study limitations. The purpose of this paper was to study
the association between cardiomyocyte injury assessed by
hsTnT levels and the risk of SCD. The highlight was meant
to be on the biological associations that help to better
understand SCD. We did not aim to build a risk prediction
model. Given the multifactorial nature of SCD and the
complex pathology, no diagnostic test exists. The incidence
of the outcome is relatively low and troponins are detected in
a signiﬁcant proportion of the population, which limits the
use of this biomarker for diagnostic purposes. Nonetheless,
a risk prediction model would require methods that are
totally different than the methods employed in this paper.
Also, the predictive value of hsTnT for SCD risk stratiﬁ-
cation purposes needs to be formally assessed and the
ﬁndings need to be replicated in a different cohort before
these could be applied in clinical practice.
The study has the inherent limitations of observational
studies, and the ﬁndings, therefore, may have been affected by
residual confounding and do not establish causality. Also, no
formal workup to rule out myocardial ischemia was per-
formed and subclinical coronary artery disease could have
been the underlying pathology. However, the associations
persisted after adjusting for an extensive number of covariates
and traditional risk factors that are usually assessed in clinical
practice as well as incident heart failure and MI, suggesting
that cardiomyocyte injury may be involved in a pathophysio-
logical process, which may lead to sudden death independent
of these conditions. Another limitation was that blood
samples were available for hsTnT assays in approximately
75% of the CHS population, which could have introduced
a bias in the overall estimates of SCD.However, this does notnegate the ﬁndings of signiﬁcant association between these
levels and SCD. The observations were made in a population
of older adults and, therefore, may not be generalized to
younger populations. Finally, there is no standard operational
deﬁnition for SCD that has consistently been used across
epidemiologic studies. Nonetheless, despite differences in
populations, study designs, the availability of clinical data,
and the operational deﬁnitions used to classify SCD, the
results of previous epidemiologic studies focusing on poten-
tial determinants of SCD typically have been consistent. In
CHS, SCD was adjudicated from medical records and
interviews with next of kin as to circumstances surrounding
the event, and most cases did not have an autopsy and heart
rhythm monitoring at the time of the sudden collapse.
Misclassiﬁcation of the outcome is possible and would tend
to underestimate the true association. Importantly, the
operational deﬁnition used to deﬁne SCD in this report
has been used in multiple previous studies (21,36–42) from
CHS, and the ﬁndings from these analyses have replicated
ﬁndings from studies with other operational deﬁnitions of
SCD. This reﬂects the fact that each of the operational
deﬁnitions seek to identify persons who experience a life-
threatening arrhythmia, or ventricular ﬁbrillation, that re-
sults in SCD in absence of successful resuscitation in the
community.
In addition to novel observations, the study has several
strengths including prospective design, relatively large pop-
ulation, inclusion of African Americans, long-term follow-
up, measures of hsTnT in a central lab, and the adjudication
of cardiovascular events by a central committee.
Conclusions
In a large community-based population, there was an asso-
ciation between both baseline and change in cardiac TnT
when measured by a highly sensitive assay and SCD risk
over long-term follow-up. This association persisted in
covariate-adjusted analyses that accounted for demographics,
baseline risk factors, and incident heart failure and MI. The
ﬁndings suggest an association between cardiomyocyte
injury in ambulatory subjects and SCD risk beyond that of
traditional risk factors.Reprint requests and correspondence: Dr. John S. Gottdiener,
Echocardiography Laboratory, University of Maryland Medical
Center, 110 South Paca Street, Floor 7, Baltimore, Mary-
land 21201. E-mail: jgottdie@medicine.umaryland.edu.REFERENCES
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